{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360021390574698112.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.3390/jcdd10050204"}},{"identifier":{"@type":"URI","@value":"https://www.mdpi.com/2308-3425/10/5/204/pdf"}},{"identifier":{"@type":"PMID","@value":"37233171"}}],"resourceType":"学術雑誌論文(journal article)","dc:title":[{"@value":"Feasibility of Short-Term Aggressive Lipid-Lowering Therapy with the PCSK9 Antibody in Acute Coronary Syndrome"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:p>Background: The guideline-recommended low-density lipoprotein cholesterol target level of <70 mg/dL may not be achieved with statin administration in some patients with acute coronary syndrome (ACS). Therefore, the proprotein convertase subtilisin-kexin type 9 (PCSK9) antibody can be added to high-risk patients with ACS. Nevertheless, the optimal duration of PCSK9 antibody administration remains unclear. Methods and Results: Patients were randomized to receive either 3 months of lipid lowering therapy (LLT) with the PCSK9 antibody followed by conventional LLT (with-PCSK9-antibody group) or 12 months of conventional LLT alone (without-PCSK9-antibody group). The primary endpoint was the composite of all-cause death, myocardial infarction, stroke, unstable angina, and ischemia-driven revascularization. A total of 124 patients treated with percutaneous coronary intervention (PCI) were randomly assigned to the two groups (n = 62 in each). The primary composite outcome occurred in 9.7% and 14.5% of the patients in the with- and without-PCSK9-antibody groups, respectively (hazard ratio: 0.70; 95% confidence interval: 0.25 to 1.97; p = 0.498). The two groups showed no significant differences in hospitalization for worsening heart failure and adverse events. Conclusions: In ACS patients who underwent PCI, short-term PCSK9 antibody therapy with conventional LLT was feasible in this pilot clinical trial. Long-term follow-up in a larger scale clinical trial is warranted.</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380021390574698123","@type":"Researcher","foaf:name":[{"@value":"Satoshi Yamashita"}],"jpcoar:affiliationName":[{"@value":"Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu 4313192, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390574698004","@type":"Researcher","foaf:name":[{"@value":"Atsushi Sakamoto"}],"jpcoar:affiliationName":[{"@value":"Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu 4313192, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1030004222006967680","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"00875411"},{"@type":"NRID","@value":"1000000875411"},{"@type":"NRID","@value":"9000411100206"},{"@type":"NRID","@value":"9000415052048"}],"foaf:name":[{"@value":"Satoshi Shoji"}],"jpcoar:affiliationName":[{"@value":"Department of Cardiology, Hino Municipal Hospital, Hino 1910062, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390574697989","@type":"Researcher","foaf:name":[{"@value":"Yoshitaka Kawaguchi"}],"jpcoar:affiliationName":[{"@value":"Department of Cardiology, Seirei Mikatahara Hospital, Hamamatsu 4338558, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390574698002","@type":"Researcher","foaf:name":[{"@value":"Yasushi Wakabayashi"}],"jpcoar:affiliationName":[{"@value":"Department of Cardiology, Seirei Mikatahara Hospital, Hamamatsu 4338558, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390574698137","@type":"Researcher","foaf:name":[{"@value":"Masaki Matsunaga"}],"jpcoar:affiliationName":[{"@value":"Department of Cardiology, Iwata City Hospital, Iwata 4388550, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390574698127","@type":"Researcher","foaf:name":[{"@value":"Kiyohisa Suguro"}],"jpcoar:affiliationName":[{"@value":"Department of Cardiology, Fujinomiya City Hospital, Fujinomiya 4180076, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390574698133","@type":"Researcher","foaf:name":[{"@value":"Yuji Matsumoto"}],"jpcoar:affiliationName":[{"@value":"Department of Cardiology, Kikugawa City Hospital, Kikugawa 4390022, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390574698126","@type":"Researcher","foaf:name":[{"@value":"Hiroyuki Takase"}],"jpcoar:affiliationName":[{"@value":"Department of Internal Medicine, Enshu Hospital, Hamamatsu 4300929, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390574698000","@type":"Researcher","foaf:name":[{"@value":"Tomoya Onodera"}],"jpcoar:affiliationName":[{"@value":"Department of Cardiology, Shizuoka City Shizuoka Hospital, Shizuoka 4208630, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390574697990","@type":"Researcher","foaf:name":[{"@value":"Kei Tawarahara"}],"jpcoar:affiliationName":[{"@value":"Department of Cardiology, Hamamatsu Red Cross Hospital, Hamamatsu 4348533, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390574698009","@type":"Researcher","foaf:name":[{"@value":"Masahiro Muto"}],"jpcoar:affiliationName":[{"@value":"Department of Cardiology, Hamamatsu Medical Center, Hamamatsu 4328580, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390574698120","@type":"Researcher","foaf:name":[{"@value":"Yasutaka Shirasaki"}],"jpcoar:affiliationName":[{"@value":"Shirasaki Clinic, Kuki 3460031, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390574697993","@type":"Researcher","foaf:name":[{"@value":"Hideki Katoh"}],"jpcoar:affiliationName":[{"@value":"Department of Cardiology, Kosai General Hospital, Kosai 4310431, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390574697988","@type":"Researcher","foaf:name":[{"@value":"Makoto Sano"}],"jpcoar:affiliationName":[{"@value":"Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu 4313192, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390574698115","@type":"Researcher","foaf:name":[{"@value":"Kenichiro Suwa"}],"jpcoar:affiliationName":[{"@value":"Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu 4313192, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390574697991","@type":"Researcher","foaf:name":[{"@value":"Yoshihisa Naruse"}],"jpcoar:affiliationName":[{"@value":"Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu 4313192, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390574698122","@type":"Researcher","foaf:name":[{"@value":"Hayato Ohtani"}],"jpcoar:affiliationName":[{"@value":"Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu 4313192, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390574698128","@type":"Researcher","foaf:name":[{"@value":"Masao Saotome"}],"jpcoar:affiliationName":[{"@value":"Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu 4313192, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390574698125","@type":"Researcher","foaf:name":[{"@value":"Tsuyoshi Urushida"}],"jpcoar:affiliationName":[{"@value":"Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu 4313192, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390574698132","@type":"Researcher","foaf:name":[{"@value":"Shun Kohsaka"}],"jpcoar:affiliationName":[{"@value":"Department of Cardiology, Keio University School of Medicine, Tokyo 1608582, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390574698001","@type":"Researcher","foaf:name":[{"@value":"Eisaku Okada"}],"jpcoar:affiliationName":[{"@value":"Department of Faculty of Social Policy and Administration, Hosei University, Tokyo 1028160, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390574698130","@type":"Researcher","foaf:name":[{"@value":"Yuichiro Maekawa"}],"jpcoar:affiliationName":[{"@value":"Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu 4313192, Japan"}]}],"publication":{"publicationIdentifier":[{"@type":"EISSN","@value":"23083425"}],"prism:publicationName":[{"@value":"Journal of Cardiovascular Development and Disease"}],"dc:publisher":[{"@value":"MDPI AG"}],"prism:publicationDate":"2023-05-09","prism:volume":"10","prism:number":"5","prism:startingPage":"204"},"reviewed":"false","dc:rights":["https://creativecommons.org/licenses/by/4.0/"],"url":[{"@id":"https://www.mdpi.com/2308-3425/10/5/204/pdf"}],"createdAt":"2023-05-10","modifiedAt":"2025-10-10","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=PCSK9%20antibody;%20acute%20coronary%20syndrome;%20lipid-lowering%20therapy;%20low-density%20lipoprotein%20cholesterol","dc:title":"PCSK9 antibody; acute coronary syndrome; lipid-lowering therapy; low-density lipoprotein cholesterol"},{"@id":"https://cir.nii.ac.jp/all?q=low-density%20lipoprotein%20cholesterol","dc:title":"low-density lipoprotein cholesterol"},{"@id":"https://cir.nii.ac.jp/all?q=lipid-lowering%20therapy","dc:title":"lipid-lowering therapy"},{"@id":"https://cir.nii.ac.jp/all?q=RC666-701","dc:title":"RC666-701"},{"@id":"https://cir.nii.ac.jp/all?q=Diseases%20of%20the%20circulatory%20(Cardiovascular)%20system","dc:title":"Diseases of the circulatory (Cardiovascular) system"},{"@id":"https://cir.nii.ac.jp/all?q=PCSK9%20antibody","dc:title":"PCSK9 antibody"},{"@id":"https://cir.nii.ac.jp/all?q=Article","dc:title":"Article"},{"@id":"https://cir.nii.ac.jp/all?q=acute%20coronary%20syndrome","dc:title":"acute coronary syndrome"}],"project":[{"@id":"https://cir.nii.ac.jp/crid/1040006432256636800","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"21K16095"},{"@type":"JGN","@value":"JP21K16095"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-21K16095/"}],"notation":[{"@language":"ja","@value":"Patient Experienceを活用した虚血性心疾患診療適正化への取り組み"},{"@language":"en","@value":"Optimizing Ischemic Heart Disease Treatment Using Patient Experience"}]}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360002218730735616","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD)"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011143502253696","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes"}]},{"@id":"https://cir.nii.ac.jp/crid/1360019302878502656","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Stepwise regression of non-culprit lipid-rich plaque observed using serial near-infrared spectroscopy–intravascular ultrasound and optical coherence tomographic measurements after aggressive cholesterol-lowering treatment: a case report"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292618784274432","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effect of Evolocumab on Coronary Plaque Composition"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292619747369088","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Long-Term Association of Low-Density Lipoprotein Cholesterol With Cardiovascular Mortality in Individuals at Low 10-Year Risk of Atherosclerotic Cardiovascular Disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1360298343119034112","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Cost-Effectiveness of Alirocumab for the Secondary Prevention of Cardiovascular Events after Myocardial Infarction in the Chinese Setting"}]},{"@id":"https://cir.nii.ac.jp/crid/1360298762198638336","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome"}]},{"@id":"https://cir.nii.ac.jp/crid/1360301788788289408","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT"}]},{"@id":"https://cir.nii.ac.jp/crid/1360584344428136832","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants"}]},{"@id":"https://cir.nii.ac.jp/crid/1360584346103081856","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The Trajectory of Lipoprotein(a) During the Peri- and Early Postinfarction Period and the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855570018730624","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Early and Late Benefits of High-Dose Atorvastatin in Patients With Acute Coronary Syndromes"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855570196970880","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855570923585664","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)"}]},{"@id":"https://cir.nii.ac.jp/crid/1360865818726722560","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"PCSK9 Inhibitors"}]},{"@id":"https://cir.nii.ac.jp/crid/1360865820413346944","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Interhospital and interindividual variability in secondary prevention: a comparison of outpatients with a history of chronic coronary syndrome versus outpatients with a history of acute coronary syndrome (the iASPIRE Study)"}]},{"@id":"https://cir.nii.ac.jp/crid/1360865820413415296","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effect of alirocumab on coronary plaque in patients with coronary artery disease assessed by optical coherence tomography"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418518776425088","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418519281613568","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469298228480","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Atorvastatin Pretreatment Improves Outcomes in Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Coronary Intervention"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469407629312","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544419182782464","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388843682799488","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"2019 ESC/EAS Guidelines for the management of dyslipidaemias:\n                    <i>lipid modification to reduce cardiovascular risk</i>"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388844932268416","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Complete Revascularization with Multivessel PCI for Myocardial Infarction"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670318747850496","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study)"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233269410254208","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes<SUBTITLE>The MIRACL Study: A Randomized Controlled Trial</SUBTITLE>"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233269441622144","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials"}]},{"@id":"https://cir.nii.ac.jp/crid/1370021390574698113","@type":"Product","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Quantifying Unmet Need in Statin-Treated Hyperlipidemia Patients and the Potential Benefit of Further LDL-C Reduction through an EHR-Based Retrospective Cohort Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1390007292691432064","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"How Do Coronary Lipid-Rich Plaques Change After Cessation of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors?　― Serial Assessment Using Near-Infrared Spectroscopy ―"},{"@value":"How Do Coronary Lipid-Rich Plaques Change after Cessation of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors?—Serial Assessment Using Near-Infrared Spectroscopy"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282680080796032","@type":"Article","resourceType":"エディトリアル(editorial)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"What Type of Statin and What Level of Low-Density Lipoprotein Cholesterol Should Be Appropriate for Secondary Prevention for Japanese Patients With Coronary Artery Disease?"},{"@value":"Intensity of Statin Therapy, Achieved Low-Density Lipoprotein Cholesterol Levels and Cardiovascular Outcomes in Japanese Patients After Coronary Revascularization"},{"@value":"Intensity of statin therapy, achieved low-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after coronary revascularization. Perspectives from the CREDO-Kyoto registry cohort-2"},{"@value":"Intensity of statin therapy, achieved LDL-C levels and cardiovascular outcomes in Japanese patients after coronary revascularization"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.3390/jcdd10050204"},{"@type":"KAKEN","@value":"PRODUCT-25057411"},{"@type":"OPENAIRE","@value":"doi_dedup___::ce2360185cbb501e461d788c0fc6f4c4"}]}